1. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170(9): 784-90.

2. Barletta JF, El-ibiary SY, Davis LE, Nguyen B, Raney CR. Proton Pump Inhibitors and the Risk for Hospital Acquired Clostridium difficile Infection. Mayo Clin Proc. 2013;88(10): 1085-90.

3. Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm. 2007;64(22):2359-63.

4. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170(9):772-8.

5. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs.JAMA. 2004;292(16): 1955-60.

6. Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMA.J. 2011;183(3):310-9.

7. Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-aly Z. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017;7(6):€015735.

8. Maggio M, Corsonello A, Ceda GP, et al. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med. 2013;173(7):518-23.

9. Heidelbaugh JJ, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol. 2006;101(10):2200-5.

10. Farrell CP, Mercogliano G, Kuntz CL. Overuse of stress ulcer prophylaxis in the critical care setting and beyond.
J Crit Care. 2010;25(2):214-20.

11. Leri F, Ayzenberg M, Voyce SJ, Klein A, Hartz L, Smego RA. Four year trends of inappropriate proton pump inhibitor use after hospital discharge. South Med J. 2013;106(4):270-3.

12. Zink DA, Pohlman M, Barnes M, Cannon ME. Long-term use of acid suppression started inappropriately during hospitalization. Aliment PharmacolTher. 2005;21(10): 1203-9.

13. Hughes GJ, Belgeri MT, Perry HM. The impact of pharmacist interventions on the inappropriate use of acid-suppression therapy. Consult Pharm. 2011;26(7):485-90.

14. Buckley MS, Park AS, Anderson CS, et al. Impact of a clinical pharmacist stress ulcer prophylaxis management program on inappropriate use in hospitalized patients. Am J Med. 2015;128(8):905-13.

15. Tasaka CL, Burg C, Vanosdol SJ, et al. An interprofessional approach to reducing the overutilization of stress ulcer prophylaxis in adult medical and surgical intensive care units. Ann Pharmacother. 2014;48(4):462-9.

16. Hatch JB, Schulz. L, Fish JT. Stress ulcer prophylaxis: reducing non-indicated prescribing after hospital discharge.
Ann Pharmacother. 2010;44(10): 1565-71.

17. Murphy CE, Stevens AM, et al. Frequency of inappropriate continuation of acid suppressive therapy after discharge in patients who began therapy in the surgical intensive care unit. Pharmacotherapy. 2008;
28(8):968-976.

18. Khalili H, Dashti-khavidaki S, Hosseintalasaz AH, Tabeefar H, Hendoiee N. Descriptive analysis of a clinical pharmacy intervention to improve the appropriate use of stress ulcer prophylaxis in a hospital infectious disease ward. J Manag Care Pharm. 2010;16(2):114-21.

19. American Society of Health-System Pharmacists. ASH therapeutic guidelines on stress ulcer prophylaxis. Am. J.
Heath-Syst Pharm. 1999;56;347-79.